Literature DB >> 8685956

Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation.

G Monti1, A Magnan, M Fattal, B Rain, M Humbert, J L Mege, M Noirclerc, P Dartevelle, J Cerrina, G Simonneau, P Galanaud, D Emilie.   

Abstract

RANTES (regulated upon activation, normally T expressed and secreted) is a chemoattractant for macrophages, memory T lymphocytes, and eosinophils. We investigated whether intrapulmonary production of the chemokine RANTES contributes to the recruitment of immune cells during lung transplantation complications. RANTES concentration was measured in bronchoalveolar lavage (BAL) fluids using an ELISA assay. It was significantly higher during CMV pneumonitis (36.2 +/- l6 pg/ml, n=12, P=0.031) and allograft rejection (31.1 +/- 8.5 pg/ml, n=27, P=0.013) than in patients without complications (9.1 +/- 2.3 pg/ml, n=22). At least some of the RANTES was produced by lung macrophages: BAL macrophages cultured for 24 hr spontaneously released larger amount of RANTES during CMV pneumonitis (140 +/- 53 pg/ml, n=8, P=0.002) and allograft rejection (84 +/- 44 pg/ml, n=11, P=0.037) than in control patients (15.2 +/- 6.5 pg/ml, n=21). Moreover, macrophages in transbronchial biopsies were labeled by an anti-RANTES mAb. RANTES production by BAL macrophages was followed in 2 patients with CMV pneumonitis. It remained high as long as CMV-induced cytopathic effects or clinical symptoms were present, but it returned to baseline as the infection was controlled. These results suggest that the intrapulmonary production of the chemokine RANTES by activated macrophages contributes to the intrapulmonary accumulation of immune cells during complications of lung transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8685956     DOI: 10.1097/00007890-199606270-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

1.  Nitric oxide mediates murine cytomegalovirus-associated pneumonitis in lungs that are free of the virus.

Authors:  K Tanaka; H Nakazawa; K Okada; K Umezawa; N Fukuyama; Y Koga
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 2.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

3.  Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration.

Authors:  J L Craigen; K L Yong; N J Jordan; L P MacCormac; J Westwick; A N Akbar; J E Grundy
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

4.  Impact of MHC class II incompatibility on localization of mononuclear cell infiltrates to the bronchiolar compartment of orthotopic lung allografts.

Authors:  Shinji Nakashima; T Rinda Soong; Karen Fox-Talbot; Zhiping Qian; Salma Rahimi; Barbara A Wasowska; Charles A Rohde; Sabrina Chen; Joe G N Garcia; William M Baldwin
Journal:  Am J Transplant       Date:  2005-04       Impact factor: 8.086

5.  Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection.

Authors:  I Nordøy; F Müller; K P Nordal; H Rollag; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

6.  Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection.

Authors:  C Agostini; F Calabrese; F Rea; M Facco; A Tosoni; M Loy; G Binotto; M Valente; L Trentin; G Semenzato
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

7.  Modulation of RANTES production by human cytomegalovirus infection of fibroblasts.

Authors:  S Michelson; P Dal Monte; D Zipeto; B Bodaghi; L Laurent; E Oberlin; F Arenzana-Seisdedos; J L Virelizier; M P Landini
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.

Authors:  S S Weigt; R M Elashoff; M P Keane; R M Strieter; B N Gomperts; Y Y Xue; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; D J Ross; J P Lynch; D A Zisman; J A Belperio
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

9.  Recipient iNOS but not eNOS deficiency reduces luminal narrowing in tracheal allografts.

Authors:  Kanji Minamoto; David J Pinsky
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

10.  In vitro pharmacoregulation of CC chemokine ligand 5 and its receptor CCR5 in diffuse lung diseases.

Authors:  Veronika Sekerova; Daniela Subrtova; Frantisek Mrazek; Agata Gibejova; Vitezslav Kolek; Roland M du Bois; Martin Petrek
Journal:  Mediators Inflamm       Date:  2003-08       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.